Mesothelioma Treatment
Mesothelioma Cancer
- Causes of Mesothelioma
- Mesothelioma Symptoms
- Mesothelioma Diagnosis
- Mesothelioma Stages
- Mesothelioma Treatment
- Innovative Mesothelioma Treatments
- Managing Mesothelioma Pain
- Nutrition Information for Mesothelioma Patients
- Specialized Mesothelioma Care
- Mesothelioma Risks
- Mesothelioma Support Groups
- Find a Mesothelioma Attorney
- Mesothelioma News
Mesothelioma Directory
Tumor Cell Vaccines With ISCOMATRIX(Trademark) Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
Get Help Today
Looking for help or additional information? Contact us today.| Conditions: | Mesolthelioma|Esophageal Cancer|Lung Cancer |
| Start Date: | December 1, 2010 |
| Phase: | Phase I |
| Status: | Recruiting |
| NCT ID: | NCT01258868 |
| Study Type: | Interventional |
| Intervention: | Drug: Celecoxib|Drug: ISCOMATRIX (TM) Adjuvant|Biological: Autologous Tumor Cell Vaccine |
| Study Design: | Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment |
| Results: | No Results Available |
| Sponsors: | National Cancer Institute (NCI) |
| Ages: | Adult|Senior |
| Enrollment: | 120 |
| Funded By: | NIH |
| First Received: | December 10, 2010 |
| End Date: | December 1, 2017 |
| Last Updated: | January 11, 2011 |
| Last Verified: | November 1, 2010 |